AzTrials
AzTrials

Peritoneal CarcinomatosisNCT05547568

A Nomogram to Predict Major Postoperative Complications After Cytoreductive Surgery and HIPEC Based on Pre and Peroperative Criteria: Which Patient Require Intensive Monitoring?

An observational study of Peritoneal Carcinomatosis, run by CHU de Reims at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

In this study, the investigators tend to highlight pre and peroperative factors that predict major postoperative complication after a surgery for resection of peritoneal carcinomatosis. Factors associated with major postoperative complications were used to elaborate un predictive nomogram model. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Peritoneal Carcinomatosis
What is being tested?
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
Type of treatment
Surgery or procedure
How many people
219 participants
Where
1 siteFrance
Study dates
Sep 2012to Jan 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients with peritoneal carcinomatosis from various origins suitable for a curative cytoreductive surgery.

Who may be able to join

  • Patients with peritoneal carcinomatosis from various origins.
  • Suitable for curative surgery
  • With a ECOG performance status ≤ 2

Who cannot join

  • Age < 18 years old

Trial locations and contacts

1 site in 1 country.

France1 site
  • Chu Reims

    Reims, 51092

Other trials in France

About this study

Official title: A Nomogram to Predict Major Postoperative Complications After Cytoreductive Surgery and HIPEC Based on Pre and Peroperative Criteria: Which Patient Require Intensive Monitoring? A Cohort Retrospective Study.

In this study, the investigators tend to highlight pre and peroperative factors that predict major postoperative complication after a surgery for resection of peritoneal carcinomatosis. Factors associated with major postoperative complications were used to elaborate un predictive nomogram model. A score was assigned for each factor of the nomogram which correspond to the weight of the association of the factor with the occurrence of the major postoperative complication. The nomogram assessed the probability of major postoperative complication after surgery by adding up the scores identified on the "Points" scale for each factor. The total score projected from the "Total points" axis to the "Risk of major postoperative complication" axis, indicated the probability of major postoperative complication occurrence. A cut-off of total score was calculated to identify patients at low or high risk for major postoperative complications. The developed nomogram may be a helpful tool to adapt postoperative monitoring of patients after surgery of peritoneal carcinomatosis resection according to the risk of occurrence of a major postoperative complication.

Read the detailed description

This is a retrospective study from a single center of a prospectively maintained database of patients who underwent cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of various primitives. The postoperative monitoring was carried out by a daily clinical examination and laboratory tests were drawn every two days during the first postoperative week. All patients had a CT-scan when a postoperative complication was suspected or at postoperative day 7 before hospital discharge. All patients were followed up to 90 postoperative days. Collected variables included age, gender and body mass index (BMI), smoking, diabetes mellitus, American Society of Anesthesiology classification of physical health (ASA), nutritional status (albuminemia ≤ 35mg/L), preoperative hemoglobin level, tumor origin, synchronous/metachronous peritoneal carcinomatosis, preoperative chemotherapy and/or biotherapy, presence of ascites at surgery, Peritoneal Cancer Index, type and number of resected organs, type and number of anastomoses, and number of packed red blood cells transfused. Wedge resection, cauterization, or superficial excisions of the bowel wall were not recorded. Minor hepatectomy concerned wedge resections or resection of less than 3 hepatic. Postoperative complications, recorded up to postoperative day 90, were graded according to Clavien-Dindo classification.

The endpoint of this study was the occurrence of a major postoperative complication that was defined as a Clavien-Dindo ≥ 3 grade complication.

To build the multivariate model the investigators used a backward stepwise approach with removal of individual variables one by one starting with the highest p-value until all variables had a p-value lower than 0.05. Results were presented as Odds Ratio and 95% confidence interval. Based on the multivariate model with identified risk factors, a nomogram was constructed to predict major postoperative complication probability after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. The coefficients derived from the multivariate analysis were used as weights. The nomogram assessed the probability of major postoperative complication after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy by adding up the scores identified on the "Points" scale for each factor. The total score projected from the "Total points" axis to the "Risk of major postoperative complication" axis, indicated the probability of major postoperative complication occurrence after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. The calibration curve of the prediction model was plotted to compare the predicted and actual probability of major postoperative complication.

The concordance index (C-index) was reported as a measure of internal validation using both 10-fold cross-validations repeated for 20 times, and bootstrap validation of 200 resamples. The area under the receiver operating characteristic (ROC) curve (AUC) was used to evaluate the performance of the model. The AUC is an effective method for quantifying the discriminatory capacity of a nomogram to correctly predict patients at low or high risk of major postoperative complication.

The Youden Index, which maximizes the sum of sensitivity and specificity, was determined according to the ROC curve. At this threshold, the sensitivity, the specificity, the predictive positive value (PPV), the negative predictive value (NPV) and the overall diagnostic accuracy (i.e., probability for a patient to be classified correctly by the nomogram) were calculated. A calibration curve was used to show consistency between the observation frequency and prediction probability.

Being tested
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
Medical subject headings
Peritoneal Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cytoreductive surgery with hyperthermic intraperitoneal chemotherapyProcedure or surgery

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Major postoperative complications (Dindo-Clavien ≥ 3 grade)

    Measured: Follow-up to 90 postoperative days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Sep 2022
  2. Study startSep 2012
  3. Primary completionJul 2021
  4. Study completionJan 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
219 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05547568
Sponsor's protocol ID
2022Ao002*
Status last verified
Oct 2022
First submitted
16 Sep 2022
Last updated
21 Oct 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Peritoneal Carcinomatosis, run by CHU de Reims at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 Oct 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Major postoperative complications (Dindo-Clavien ≥ 3 grade) (time frame: Follow-up to 90 postoperative days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Oct 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in